Synapse - Hematologic Malignancies, Division of

Search Within

Hematologic Malignancies, Division of

Results (13379)

MYLOX-1: An open-label, phase IIa study of the safety, tolerability, pharmacokinetics and pharmacodynamics of oral LOXL2 inhibitor, GB2064, in myelofibrosis

Meeting Abstract

Verstovsek, S.; Mascarenhas, J.; Rampal, R. K.; Cilloni, D.; Harrison, C.; Jacoby, B.; Slack, R. J.; Aslanis, V.; Singh, B.; Lindmark, B.
Blood (2022)

Fulltext@MSK | Save

Asciminib as initial therapy for patients with chronic myeloid leukemia in chronic phase (CML-CP)-H. Jean Khoury Cure CML Consortium study

Meeting Abstract

Atallah, E. L.; Visotcky, A.; Flynn, K. E.; Zhang, M. J.; Radich, J. P.; Yang, J.; Oehler, V. G.; Tantravahi, S. K.; Smith, B. D. D.; Ibarz, J. P.; more...
Blood (2022)

Fulltext@MSK | Save

Long-term molecular testing and clinical response of tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: 5-year follow-up from SIMPLICITY, a prospective, observational study

Meeting Abstract

Cortes, J. E.; Goldberg, S. L.; Paquette, R.; Williams, L. A.; Hehlmann, R.; Michallet, M.; Gambacorti-Passerini, C.; Tang, D. R.; DeGutis, I. S.; McBride, A.; more...
Blood (2022)

Fulltext@MSK | Save

Molecularly targeted combination therapy for advanced phase myeloproliferative neoplasm: MPN-RC 119

Meeting Abstract

Bar-Natan, M.; Mascarenhas, J.; Gerds, A. T.; Mesa, R.; Gupta, V.; Kremyanskaya, M.; Dougherty, M.; Fabris, F.; Johnson, K.; Yu, A.; more...
Blood (2022)

Fulltext@MSK | Save

Escape from type II JAK2 inhibition in MPN depends on AXL/MAPK activation and is targetable

Meeting Abstract

Codilupi, T.; Szybinski, J.; Brkic, S.; Stivala, S.; Yang, J.; Ghosh, N.; Buczak, K.; Passweg, J.; Angelillo-Scherrer, A.; Dirnhofer, S.; more...
Blood (2022)

Fulltext@MSK | Save

Long-term outcome of patients with follicular lymphoma is not fundamentally affected by KMT2D, EZH2, and CREBBP mutational status

Meeting Abstract

Bantilan, K. S.; Rutherford, K.; McCarter, J.; Farnoud, N.; Arango-Ossa, J. E.; Papaemmanuil, E.; Zelenetz, A. D.
Blood (2022)

Fulltext@MSK | Save

Identifying primary refractory disease and early relapses in peripheral T-cell lymphoma using baseline characteristics, minimal residual disease, and mutational profiling

Meeting Abstract

Stuver, R.; Haynie, H.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Mazloom, A.; Moskowitz, A. J.; Drill, E.; Horwitz, S. M.
Blood (2022)

Fulltext@MSK | Save

Outcomes for patients with relapsed and refractory peripheral T-cell lymphoma in the 21st century by relapse status, salvage therapy, and receipt of allogeneic transplant

Meeting Abstract

Stuver, R.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Sauter, C. S.; Scordo, M.; Shah, G. L.; Moskowitz, A. J.; Horwitz, S. M.
Blood (2022)

Fulltext@MSK | Save

Emapalumab for malignancy-associated hemophagocytic lymphohistiocytosis: The Memorial Sloan Kettering Cancer Center experience

Meeting Abstract

Johnson, W. T.; Epstein-Peterson, Z. D.; Ganesan, N.; Chang, T.; Galasso, N.; Stuver, R.; Khan, N.; Salles, G.; Moskowitz, A. J.; Vardhana, S.; more...
Blood (2022)

Fulltext@MSK | Save

Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs): Updated results from a phase I/II study

Meeting Abstract

Budde, E. L.; Bartlett, N. L.; Giri, P.; Schuster, S. J.; Assouline, S.; Yoon, S. S.; Fay, K.; Matasar, M. J.; Gutierrez, N. C.; Marlton, P.; more...
Blood (2022)

Fulltext@MSK | Save